KRAS, EGFR MUTATIONS AND EGFR GENE COPY STATUS AS PREDICTIVE MARKERS OF RESPONSE AND TIME TO PROGRESSION IN EGFR WILD-TYPE STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH EGFR TYROSINE-KINASE INHIBITORS.
JOURNAL OF THORACIC ONCOLOGY(2013)
Key words
Biomarkers,Tirosine-kinase inhibitors,NSCLC,metastatic
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined